
Daniela Verthelyi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5005270/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs. Journal of Immunology, 2001, 166, 2372-2377.	0.8	493
2	Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality. Journal of Pharmaceutical Sciences, 2009, 98, 1201-1205.	3.3	492
3	GM-CSF Production by Autoreactive T Cells Is Required for the Activation of Microglial Cells and the Onset of Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2007, 178, 39-48.	0.8	338
4	Sex hormones as immunomodulators in health and disease. International Immunopharmacology, 2001, 1, 983-993.	3.8	317
5	Use of CpG oligodeoxynucleotides as immune adjuvants. Immunological Reviews, 2004, 199, 201-216.	6.0	270
6	CpG Oligodeoxynucleotides as Vaccine Adjuvants in Primates. Journal of Immunology, 2002, 168, 1659-1663.	0.8	184
7	Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nature Biotechnology, 2008, 26, 901-908.	17.5	148
8	Zika (PRVABC59) Infection Is Associated with T cell Infiltration and Neurodegeneration in CNS of Immunocompetent Neonatal C57Bl/6 Mice. PLoS Pathogens, 2016, 12, e1006004.	4.7	146
9	Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. Journal of Leukocyte Biology, 2002, 71, 813-20.	3.3	127
10	Immune Recognition of Foreign DNA. Immunity, 1999, 11, 123-129.	14.3	122
11	Glycosylation, Hypogammaglobulinemia, and Resistance to Viral Infections. New England Journal of Medicine, 2014, 370, 1615-1625.	27.0	117
12	CpG Oligodeoxynucleotides Protect Normal and SIV-Infected Macaques from <i>Leishmania</i> Infection. Journal of Immunology, 2003, 170, 4717-4723.	0.8	109
13	Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides. Veterinary Microbiology, 2001, 78, 353-362.	1.9	102
14	Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. European Journal of Immunology, 2007, 37, 1785-1795.	2.9	101
15	Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends in Immunology, 2003, 24, 519-522.	6.8	100
16	Expression profiles of human interferonâ€alpha and interferonâ€lambda subtypes are ligand†and cellâ€dependent. Immunology and Cell Biology, 2012, 90, 774-783.	2.3	97
17	Managing uncertainty: A perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. Journal of Pharmaceutical Sciences, 2012, 101, 3560-3567.	3.3	91
18	CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. European Journal of Immunology, 2002, 32, 2617-2622.	2.9	84

DANIELA VERTHELYI

#	Article	IF	CITATIONS
19	The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Nature Immunology, 2020, 21, 1146-1151.	14.5	82
20	Reduction of CpC-induced arthritis by suppressive oligodeoxynucleotides. Arthritis and Rheumatism, 2002, 46, 2219-2224.	6.7	81
21	Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clinical Immunology, 2003, 109, 64-71.	3.2	81
22	Coinjection with CpG-Containing Immunostimulatory Oligodeoxynucleotides Reduces the Pathogenicity of a Live Vaccine against Cutaneous Leishmaniasis but Maintains Its Potency and Durability. Infection and Immunity, 2003, 71, 5121-5129.	2.2	69
23	CpG Oligodeoxynucleotides Protect Newborn Mice from a Lethal Challenge with the Neurotropic Tacaribe Arenavirus. Journal of Immunology, 2006, 176, 4940-4949.	0.8	67
24	Scientific considerations in the review and approval of generic enoxaparin in the United States. Nature Biotechnology, 2013, 31, 220-226.	17.5	67
25	CpG DNA: recognition by and activation of monocytes. Microbes and Infection, 2002, 4, 897-901.	1.9	64
26	Detection of Innate Immune Response Modulating Impurities in Therapeutic Proteins. PLoS ONE, 2015, 10, e0125078.	2.5	55
27	Prevention and Treatment of Cutaneous Leishmaniasis in Primates by Using Synthetic Type D/A Oligodeoxynucleotides Expressing CpG Motifs. Infection and Immunity, 2005, 73, 4948-4954.	2.2	54
28	Trace Levels of Innate Immune Response Modulating Impurities (IIRMIs) Synergize to Break Tolerance to Therapeutic Proteins. PLoS ONE, 2010, 5, e15252.	2.5	53
29	CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques. Aids, 2004, 18, 1003-1008.	2.2	45
30	ZIKA virus infection causes persistent chorioretinal lesions. Emerging Microbes and Infections, 2018, 7, 1-15.	6.5	45
31	2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3 – LBA/cell-based assays: immunogenicity, biomarkers and PK) Tj ETQq1 1	0.784314	∙rg₿₮ /Overic
32	Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants. Biomaterials, 2008, 29, 4808-4814.	11.4	39
33	TLR9 and TLR7 agonists mediate distinct type I IFN responses in humans and nonhuman primates in vitro and in vivo. Journal of Leukocyte Biology, 2011, 91, 147-158.	3.3	35
34	2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (<u>Part 3</u> –) Tj ETQq0 0 0 r	gBT /Over 1.5	ock 10 Tf 50 31
35	415-463. Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugs. Nucleic Acids Research, 2005, 33, 3550-3560.	14.5	30
36	Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates. Nucleic Acids Research, 2006, 34, 6488-6495.	14.5	30

DANIELA VERTHELYI

#	Article	IF	CITATIONS
37	Regulatory T Cells in $\hat{1}^3$ Irradiation-Induced Immune Suppression. PLoS ONE, 2012, 7, e39092.	2.5	29
38	Regulation of the maturation of human monocytes into immunosuppressive macrophages. Blood Advances, 2017, 1, 2510-2519.	5.2	29
39	Pseudovirus rVSVΔC-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice. Cell Reports, 2019, 26, 1718-1726.e4.	6.4	29
40	Long-term persistence of infectious Zika virus: Inflammation and behavioral sequela in mice. PLoS Pathogens, 2020, 16, e1008689.	4.7	29
41	Immunotherapy with CpG Oligonucleotides and Antibodies to TNF-α Rescues Neonatal Mice from Lethal Arenavirus-Induced Meningoencephalitis. Journal of Immunology, 2008, 180, 8231-8240.	0.8	28
42	The acceleration of wound healing in primates by the local administration of immunostimulatory CpG oligonucleotides. Biomaterials, 2011, 32, 4238-4242.	11.4	28
43	2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 – PK, PD & ADA assays by hybrid LBA/LCMS & regulatory) Tj ETQq1 I	l 017 8 4314	r g8 T /Overle
44	Aggregates of IVIG or Avastin, but not HSA, modify the response to model innate immune response modulating impurities. Scientific Reports, 2018, 8, 11477.	3.3	25
45	Mucosal and Peripheral Lin ^{â^'} HLA-DR ⁺ CD11c/123 ^{â^'} CD13 ⁺ CD14 ^{â^'} Mononuclear Cells Are Preferentially Infected during Acute Simian Immunodeficiency Virus Infection. Journal of Virology, 2012, 86, 1069-1078.	3.4	24
46	Non-animal replacement methods for human vaccine potency testing: state of the science and future directions. Procedia in Vaccinology, 2011, 5, 16-32.	0.4	23
47	Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety. Seminars in Immunopathology, 2000, 22, 173-184.	4.0	23
48	Cell based assay identifies TLR2 and TLR4 stimulating impurities in Interferon beta. Scientific Reports, 2017, 7, 10490.	3.3	20
49	InÂVivo Effect of Innate Immune Response Modulating Impurities on the Skin Milieu Using a Macaque Model: Impact on Product Immunogenicity. Journal of Pharmaceutical Sciences, 2017, 106, 751-760.	3.3	19
50	CD4 and CD8 T cells mediate distinct lethal meningoencephalitis in mice challenged with Tacaribe arenavirus. Cellular and Molecular Immunology, 2017, 14, 90-107.	10.5	19
51	IL-6 Impairs Vaccine Responses in Neonatal Mice. Frontiers in Immunology, 2018, 9, 3049.	4.8	19
52	2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs (<u>Part 2</u> – Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV) Tj E Bioanalysis, 2019, 11, 2099-2132.	TQ <u>q</u> 0 0 0 r	gBT /Overloc
53	Expression and regulation in the brain of the chemokine CCL27 gene locus. Journal of Neuroimmunology, 2010, 225, 82-90.	2.3	17
54	CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis. PLoS Neglected Tropical Diseases, 2020, 14,	3.0	17

DANIELA VERTHELYI

#	ARTICLE	IF	CITATIONS
55	2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory FeedbackÂ(<u>Part 2A</u> – Recommendations on) Tj ETQq1 1 0.7	84314 rg 1.5	BT /Overlock 16
56	PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses. Thrombosis Research, 2017, 159, 39-47.	1.7	14
57	Adjuvant Properties of CpG Oligonucleotides in Primates. , 2006, 127, 139-158.		11
58	Assessment of the cellular internalization of thermolytic phosphorothioate DNA oligonucleotide prodrugs. Bioorganic and Medicinal Chemistry, 2013, 21, 6224-6232.	3.0	11
59	CpG Oligonucleotides Protect Mice From Alphavirus Encephalitis: Role of NK Cells, Interferons, and TNF. Frontiers in Immunology, 2020, 11, 237.	4.8	8
60	High-Throughput Quantitative Real-Time Polymerase Chain Reaction Array for Absolute and Relative Quantification of Rhesus Macaque Types I, II, and III Interferon and Their Subtypes. Journal of Interferon and Cytokine Research, 2012, 32, 407-415.	1.2	7
61	An In Vitro Assessment of Immunostimulatory Responses to Ten Model Innate Immune Response Modulating Impurities (IIRMIs) and Peptide Drug Product, Teriparatide. Molecules, 2021, 26, 7461.	3.8	7
62	NK cells require immune checkpoint receptor LILRB4/gp49B to control neurotropic Zika virus infections in mice. JCI Insight, 2022, 7, .	5.0	5
63	Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVI "G-EBOV-GP infection model. Emerging Microbes and Infections, 2021, 10, 2076-2089.	6.5	3
64	Design and Development of Thermolytic DNA Oligonucleotide Prodrugs. Annals of the New York Academy of Sciences, 2005, 1058, 26-38.	3.8	2
65	Immunogenicity Risks for Naturally Derived Complex Drugs. AAPS Advances in the Pharmaceutical Sciences Series, 2019, , 219-244.	0.6	0
66	Title is missing!. , 2020, 14, e0008050.		0
67	Title is missing!. , 2020, 14, e0008050.		0

68 Title is missing!. , 2020, 14, e0008050.

0